12 Month Price Forecast For LXEO
Distance to LXEO Price Forecasts
LXEO Price Momentum
๐ค Considering Lexeo Therapeutics (LXEO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 4:06 AM UTC
LXEO Analyst Ratings & Price Targets
Based on our analysis of 8 Wall Street analysts, LXEO has a consensus that is bullish. The median price target is $23.00, with forecasts ranging from $16.00 to $28.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With LXEO currently trading at $4.95, the median price forecast suggests a 364.6% upside. The most optimistic forecast comes from Brian Skorney at Baird, projecting a 465.7% upside, while at provides the most conservative target, suggesting a 223.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LXEO Analyst Consensus
LXEO Price Target Range
Latest LXEO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LXEO.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 21, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $24.00 |
Nov 14, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $23.00 |
Nov 13, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $25.00 |
Nov 13, 2024 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $19.00 |
Oct 31, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $21.00 |
Oct 30, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $23.00 |
Oct 25, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $23.00 |
Aug 14, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $23.00 |
Aug 13, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $24.00 |
Aug 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $21.00 |
Jul 16, 2024 | Chardan Capital | Buy | Maintains | $0.00 | |
Jul 16, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $22.00 |
Jul 15, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $23.00 |
Jun 13, 2024 | Baird | Brian Skorney | Outperform | Initiates | $28.00 |
Jun 6, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $22.00 |
Mar 12, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $24.00 |
Nov 28, 2023 | Chardan Capital | Geulah Livshits | Buy | Initiates | $23.00 |
Nov 28, 2023 | RBC Capital | Luca Issi | Outperform | Initiates | $22.00 |
Nov 28, 2023 | Stifel | Paul Matteis | Buy | Initiates | $20.00 |
Nov 28, 2023 | Leerink Partners | Mani Foroohar | Outperform | Initiates | $19.00 |
Stocks Similar to Lexeo Therapeutics, Inc.
The following stocks are similar to Lexeo Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Lexeo Therapeutics, Inc. (LXEO) Financial Data
Lexeo Therapeutics, Inc. has a market capitalization of $179.28M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -74.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Lexeo Therapeutics, Inc. (LXEO) Company Overview
About Lexeo Therapeutics, Inc.
Develops gene therapies for genetic diseases.
The company operates as a clinical stage genetic medicine firm, focusing on developing gene therapy candidates targeting hereditary and acquired diseases. It generates potential revenue through the successful development and commercialization of its therapies, particularly those aimed at serious conditions such as cardiomyopathies and Batten disease.
Lexeo Therapeutics was incorporated in 2017 and is headquartered in New York, New York. It is currently in the clinical stages of its therapies, which could lead to significant market opportunities if successful in clinical trials and regulatory approvals.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
69
CEO
Mr. R. Nolan Townsend
Country
United States
IPO Year
N/A
Website
www.lexeotx.comLexeo Therapeutics, Inc. (LXEO) Latest News & Analysis
Lexeo Therapeutics (Nasdaq: LXEO) announced CEO R. Nolan Townsend will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 7, 2025.
Lexeo Therapeutics' CEO presenting at a major conference may signal potential investor interest, market visibility, and updates on their genetic treatments, impacting stock performance.
Lexeo Therapeutics appointed Dr. Kyle Rasbach as Chief Financial Officer, effective immediately. The company focuses on gene therapies for cardiovascular diseases and Alzheimer's, with key developments expected soon.
Dr. Rasbach's appointment signals potential strategic shifts and financial stability for Lexeo Therapeutics, which may influence investor confidence amidst upcoming program developments.
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
2 months agoLexeo Therapeutics reached FDA alignment on registrational endpoints for LX2006, received RMAT designation, and completed enrollment in key trials. It has $157M in cash, ensuring operational support until 2027.
FDA alignment on LX2006's development plan and RMAT designation suggest a faster route to market, potentially boosting investor confidence and stock value for Lexeo Therapeutics.
Lexeo Therapeutics reported positive interim data for LX1001, the first gene therapy targeting the genetic cause of APOE4-associated Alzheimer's disease.
Positive interim data for LX1001 could indicate a breakthrough in Alzheimer's treatment, potentially increasing Lexeo Therapeutics' stock value and attracting investor interest in biotech innovations.
Lexeo Therapeutics (Nasdaq: LXEO) will present interim data on LX1001, a gene therapy for Alzheimer's, at the CTAD conference from Oct 29-Nov 1, 2024, highlighting safety and biomarker findings.
The late-breaking presentation of LX1001's interim data at a major conference highlights potential breakthroughs in Alzheimer's treatment, which could significantly impact Lexeo Therapeutics' stock and investor sentiment.
Lexeo Therapeutics (Nasdaq: LXEO) will present at upcoming investor conferences, focusing on its work in genetic treatments for cardiovascular diseases and Alzheimer's.
Lexeo Therapeutics' participation in investor conferences signals active engagement with the investment community, potentially boosting investor interest and stock performance.
Frequently Asked Questions About LXEO Stock
What is Lexeo Therapeutics, Inc.'s (LXEO) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Lexeo Therapeutics, Inc. (LXEO) has a median price target of $23.00. The highest price target is $28.00 and the lowest is $16.00.
Is LXEO stock a good investment in 2025?
According to current analyst ratings, LXEO has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LXEO stock?
Wall Street analysts predict LXEO stock could reach $23.00 in the next 12 months. This represents a 364.6% increase from the current price of $4.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lexeo Therapeutics, Inc.'s business model?
The company operates as a clinical stage genetic medicine firm, focusing on developing gene therapy candidates targeting hereditary and acquired diseases. It generates potential revenue through the successful development and commercialization of its therapies, particularly those aimed at serious conditions such as cardiomyopathies and Batten disease.
What is the highest forecasted price for LXEO Lexeo Therapeutics, Inc.?
The highest price target for LXEO is $28.00 from Brian Skorney at Baird, which represents a 465.7% increase from the current price of $4.95.
What is the lowest forecasted price for LXEO Lexeo Therapeutics, Inc.?
The lowest price target for LXEO is $16.00 from at , which represents a 223.2% increase from the current price of $4.95.
What is the overall LXEO consensus from analysts for Lexeo Therapeutics, Inc.?
The overall analyst consensus for LXEO is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $23.00.
How accurate are LXEO stock price projections?
Stock price projections, including those for Lexeo Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.